3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
4
Carcinoid Tumor
3
Pheochromocytoma
1
Paraganglioma
1
Neoplasm Metastasis
1
Gastrointestinal Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
lutetium Lu 177 dotatate
4
Temozolomide
4
anlotinib
3
Specimen Handling
3
cabozantinib
2
belzutifan
2
Sunitinib
2
Magnetic Resonance Spectroscopy
2
Axitinib
2
3-Iodobenzylguanidine
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
talazoparib
1
pembrolizumab
1
pazopanib
1
olaparib
1
lanreotide
1
guadecitabine
1
gallium Ga 68 dotatate
1
copper dotatate CU-64
1
atezolizumab
1
ONC206
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Ipilimumab
1
Fluorodeoxyglucose F18
1
Everolimus
1
Erlotinib Hydrochloride
1
Contrast Media
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Paraganglioma
×
lanreotide
×
Clear all
NCT03946527
2026-03-02
LAMPARA
Columbia University
Phase 2
Active not recruiting
10 enrolled